Cell Reports (Jan 2013)

S6K1 Alternative Splicing Modulates Its Oncogenic Activity and Regulates mTORC1

  • Vered Ben-Hur,
  • Polina Denichenko,
  • Zahava Siegfried,
  • Avi Maimon,
  • Adrian Krainer,
  • Ben Davidson,
  • Rotem Karni

DOI
https://doi.org/10.1016/j.celrep.2012.11.020
Journal volume & issue
Vol. 3, no. 1
pp. 103 – 115

Abstract

Read online

Ribosomal S6 kinase 1 (S6K1) is a major mTOR downstream signaling molecule that regulates cell size and translation efficiency. Here, we report that short isoforms of S6K1 are overproduced in breast cancer cell lines and tumors. Overexpression of S6K1 short isoforms induces transformation of human breast epithelial cells. The long S6K1 variant (Iso-1) induced opposite effects. It inhibits Ras-induced transformation and tumor formation, while its knockdown or knockout induces transformation, suggesting that Iso-1 has a tumor-suppressor activity. Furthermore, we found that S6K1 short isoforms bind and activate mTORC1, elevating 4E-BP1 phosphorylation, cap-dependent translation, and Mcl-1 protein levels. Both a phosphorylation-defective 4E-BP1 mutant and the mTORC1 inhibitor rapamycin partially blocked the oncogenic effects of S6K1 short isoforms, suggesting that these are mediated by mTORC1 and 4E-BP1. Thus, alternative splicing of S6K1 acts as a molecular switch in breast cancer cells, elevating oncogenic isoforms that activate mTORC1.